ReproCell Stock

ReproCell Financing Cash Flow

The Net Financing Cash Flow of ReproCell (4978.T) as of Sep 11, 2026 is 680.11 M JPY. In the previous year, Net Financing Cash Flow was 544.05 M JPY — a change of 25.01% (higher).

Financing Cash Flow

680.11 MJPY

YoY

25.01%

Last updated:

Net Financing Cash Flow of ReproCell is 2026 680.11 M JPY. Net Financing Cash Flow of ReproCell was 2025 544.05 M JPY. It decreases by 25.01% higher compared to the previous year.

The ReproCell Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
1.03 B JPY
Jan 1, 2019
1.38 B JPY
Jan 1, 2020
6.57 M JPY
Jan 1, 2021
4.41 M JPY
Jan 1, 2022
2.38 B JPY
Jan 1, 2023
482.87 M JPY
Jan 1, 2024
544.05 M JPY
Jan 1, 2025
680.11 M JPY
The ReproCell Financing Cash Flow history
YEARFinancing Cash FlowYoY
680.11 MJPY+25.01%
544.05 MJPY+12.67%
482.87 MJPY-79.75%
2.38 BJPY+53,976.05%
4.41 MJPY-32.84%
6.57 MJPY-99.52%
1.38 BJPY+34.27%
1.03 BJPY-8.78%
1.13 BJPY-33.67%
1.70 BJPY-15.68%
2.02 BJPY-59.81%
5.02 BJPY
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Net Financing Cash Flow of ReproCell is 680.11 M JPY in 2026.

Net Financing Cash Flow of ReproCell changed from 544.05 M JPY to 680.11 M JPY, representing a 25.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow ReproCell since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's ReproCell historically and in real time.

Access this data via the Eulerpool API

Cash Flow — ReproCell

All Key Metrics — ReproCell